RADIANT was a randomized, double-blind, controlled phase 3 study evaluating whether adjuvant erlotinib could improve survival in completely resected stage IB to IIIA NSCLC when positive EGFR by immunohistochemistry or EGFR amplification by fluorescence in situ hybridization was identified. Here, EGFR is linked to non-small cell lung carcinoma.